FDA Approves New Prostate Cancer Imaging Agent Gozellix
Filed with ASX · · 3 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Completes FAP-Targeting Theranostic Acquisition
- FDA accepts BLA and grants priority review for Zircaix
- Telix Announces Change in Reporting Currency to USD
- 2024 Full Year Results Presentation
- 2024 Full Year Results Announcement
Later from Telix Pharmaceuticals
- Telix Reports US$186M Q1 Revenue, Up 62% YOY
- Telix Provides Regulatory Update on TLX101-CDx
- Telix's Illuccix PSMA-PET Imaging Agent Approved in France
- Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
- Illuccix China Phase 3 Study Completes Enrolment
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals